Active substance
Cefixime
- SFDA 33
- US FDA 17
- Health Canada 4
- US price lines 3
- NHS prices 1
- WHO EML 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CEFIM 100 POWDER FOR ORAL SUSPENTION | 20 mg/ml | Suspension · Oral use | 1 Bottle | SAR 36.30 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| CEFIM 200MG CAPSULES | 200 mg | Capsule · Oral use | 8 Blister | SAR 44.70 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| CEFIM 400MG CAPSULES | 400 mg | Capsule · Oral use | 6 Blister | SAR 45.95 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| CEFIX 100MG-5ML SUSPENSION | 20 mg/ml | Suspension · Oral use | 1 Bottle | SAR 34.75 | Generic · Prescription | Pharma International Co. | Valid |
| CEFIX 200MG CAPSULES | 200 mg | Capsule, hard · Oral use | 8 Blister | SAR 36.30 | Generic · Prescription | Pharma International Co. | Valid |
| CEFIX 400MG CAPSULES | 400 mg | Capsule, hard · Oral use | 6 Blister | SAR 45.80 | Generic · Prescription | Pharma International Co. | Valid |
| CEFRAX 400MG CAPSULES | 400 mg | Capsule · Oral use | 6 Blister | SAR 49.55 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| MAGNACEF 100MG\5ML SUSP | 20 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 36.60 | Generic · Prescription | Ram Pharmaceutical Industries | Valid |
| MAGNACEF 200MG CAP. | 200 mg | Capsule · Oral use | 8 Blister | SAR 46.65 | Generic · Prescription | Ram Pharmaceutical Industries | Valid |
| MAGNACEF 400MG CAP | 400 mg | Capsule · Oral use | 6 Blister | SAR 67.55 | Generic · Prescription | Ram Pharmaceutical Industries | Valid |
| MIDIXIME 100MG\5ML | 20 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 19.95 | Generic · Prescription | Med City Pharma | Valid |
| MIDIXIME 200 mg Capsules | 200 mg | Capsule · Oral use | 8 Blister | SAR 21.75 | Generic · Prescription | Med City Pharma | Valid |
| MIDIXIME 400 mg Capsules | 400 mg | Capsule · Oral use | 6 Blister | SAR 34.70 | Generic · Prescription | Med City Pharma | Valid |
| MIXIF | 20 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 25.15 | Generic · Prescription | DAR ALDAWA | Valid |
| MIXIF 400 mg Capsules | 400 mg | Capsule · Oral use | 5 Blister | SAR 41.30 | Generic · Prescription | DAR ALDAWA | Valid |
| Mixif | 400 mg | Capsule, hard · Oral use | 10 Blister | SAR 75.50 | Generic · Prescription | DAR ALDAWA | Valid |
| SUPRAX 100 SUSP | 20 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 44.95 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| SUPRAX 200 CAPS | 200 mg | Capsule · Oral use | 8 Blister | SAR 48.85 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| SUPRAX 400 CAPS | 400 mg | Capsule · Oral use | 6 Blister | SAR 72.50 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| SUPRAX D 400MG TABLET | 400 mg | Dispersible tablet · Oral use | 6 Blister | SAR 72.50 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Suprax | 40 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 74.90 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| WINEX 100MG\5ML ORAL SUSP | 20 mg/ml | Suspension · Oral use | 1 Bottle | SAR 40.35 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| WINEX 200MG CAP | 200 mg | Capsule · Oral use | 8 Blister | SAR 49.65 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| WINEX 400MG CAP | 400 mg | Capsule · Oral use | 6 Blister | SAR 67.95 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| APEX 400MG CAPSULE | 400 mg | Capsule · Oral use | 6 Blister | SAR 49.55 | Generic · Prescription | RETAJ Pharmaceutical Industries | Withdrawn by regulatory authority · Not Marketed |
8 more — full table
Indications — CHI Daman Drug Formulary
ACUTE BACTERIAL PROSTATITIS; ACUTE PYELONEPHRITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; LOWER URINARY TRACT INFECTIONS; MUCOPURULENT CONJUCTIVITIS - GONOCOCCAL INFECTION OF THE EYE; ORCHITIS AND EPIDIDYMITIS; OSTEOMYELITIS; Pyogenic Arthritis; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SUPRAX | 200MG/5ML | for suspension · oral | LUPIN PHARMS | Prescription | 10 Apr 2007 |
| SUPRAX | 400MG | capsule · oral | LUPIN LTD | Prescription | 1 Jun 2012 |
| SUPRAX | 500MG/5ML | for suspension · oral | LUPIN LTD | Prescription | 20 Feb 2013 |
| CEFIXIME | 100MG/5ML; 200MG/5ML | for suspension · oral | AUROBINDO PHARMA LTD | Prescription | 14 Apr 2015 |
| CEFIXIME | 100MG/5ML; 200MG/5ML | for suspension · oral | AJENAT PHARMS | Prescription | 6 Feb 2017 |
| CEFIXIME | 500MG/5ML | for suspension · oral | AJENAT PHARMS | Prescription | 6 Feb 2017 |
| CEFIXIME | 400MG | capsule · oral | ALKEM LABS LTD | Prescription | 9 Oct 2018 |
| CEFIXIME | 100MG/5ML; 200MG/5ML | for suspension · oral | ALKEM LABS LTD | Prescription | 19 Feb 2021 |
| CEFIXIME | 400MG | tablet · oral | FDC LTD | Prescription | 17 Dec 2024 |
| CEFIXIME | 400MG | capsule · oral | AUROBINDO PHARMA LTD | Prescription | 23 Mar 2026 |
| CEFIXIME | 100MG/5ML; 200MG/5ML | for suspension · oral | FDC LTD | Prescription | 14 May 2026 |
| SUPRAX | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | LEDERLE | Discontinued | 28 Apr 1989 |
| SUPRAX | 100MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | for suspension · oral | LEDERLE | Discontinued | 28 Apr 1989 |
| SUPRAX | 400MG | tablet · oral | LUPIN PHARMS | Discontinued | 12 Feb 2004 |
| SUPRAX | 100MG/5ML | for suspension · oral | LUPIN PHARMS | Discontinued | 23 Feb 2004 |
| SUPRAX | 100MG; 150MG; 200MG | tablet, chewable · oral | LUPIN LTD | Discontinued | 25 Oct 2010 |
| CEFIXIME | 100MG/5ML; 200MG/5ML | for suspension · oral | CHARTWELL RX | Discontinued | 17 Nov 2017 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-CEFIXIME | 02432773 | 400 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CEFIXIME | 02468689 | 100 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | AURO PHARMA INC |
| SUPRAX | 00868965 | 100 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | ODAN LABORATORIESLTD |
| SUPRAX | 00868981 | 400 MG | TABLET · ORAL | ODAN LABORATORIESLTD |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CEFIXIME 100 MG/5 ML SUSP | $2.44303 | per ML | 23 Sep 2026 |
| US NADAC | CEFIXIME 200 MG/5 ML SUSP | $3.42661 | per ML | 23 Sep 2026 |
| US NADAC | CEFIXIME 400 MG CAPSULE | $10.02817 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Cefixime 200mg tablets | £13.23 | 7 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · core
Second choice: Infectious gastroenteritis or colitis without specification of infectious agent; Second choice: Gonococcal infection (co-prescribed with azithromycin)
Oral > Liquid: 100 mg per 5 mL powder for oral liquid (EMLc) | Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
Safety signals and safety-related labeling changes
- US FDA 22 May 2025 SUPRAX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Oct 2019 SUPRAX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.